Built on the standardized GA-map® platform, GA-map® Discovery is a comprehensive end-to-end microbiota research service for gut and oral microbiota profiling. Comprising more than 170 bacteria markers, the GA-map® Discovery was developed to facilitate the discovery of new biomarkers and bacteria signatures associated with health and disease. GA-map® Discovery is a perfect choice for comparative studies of different disease cohorts, treatment responses, and more. The launch of GA-map ® Discovery brings to the market a research service with high accuracy, exceptional reproducibility, and short turnaround time, enabling cost-effective microbiota measurements.

The GA-map® Discovery is GA's first dedicated offering in the research market. In recent years, microbiome research has witnessed considerable growth, fuelling new inventions in disease diagnostics, treatment selection and monitoring, and disease prevention. The research market for microbiome measurement was valued at $859 million in 2021 and is projected to reach $3,417 million by 2031 [(1)].

Ronny Hermansen, CEO of Genetic Analysis, comments:
"We are excited to announce our complete offering to this fast-growing research market; the GA-map Discovery, underlines GA's innovative position in the microbiome space. GA has developed this broad panel of markers to facilitate the needs of academia and industry in their microbiome research. I am proud of our ability to deliver this product as it highlights our team's dedication to pioneering microbiome diagnostics."

1. https://www.alliedmarketresearch.com/microbiome-sequencing-market-A13576